Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

Share Price is delayed by 15 minutes
Get Live Data
520.00    0.00 (0.00%)
Bid:
516.00
Ask:
520.00
Spread: 4.00 (0.775%)
Market Cap: £860.42m
OCI Live PriceLast checked at - London Stock Exchange

Intraday Oakley Share Chart

COVID-19 Update

25 Mar 2020 07:00

RNS Number : 4723H
Oakley Capital Investments Limited
25 March 2020
 

25 March 2020

Oakley Capital Investments Limited

 

COVID-19 Update

 

The Board of Oakley Capital Investments Limited1 (the "Company" or "OCI"), would like to provide an update in light of the COVID-19 pandemic and its global impact.

 

OCI and Oakley Capital, the Investment Adviser3, are placing the safety and welfare of its colleagues, investors, and all other stakeholders as its highest priority and are taking all necessary steps to protect individuals, ensure business continuity and provide support to our portfolio companies.

 

Oakley Capital has increasingly focused on investing in companies that provide software solutions and digital infrastructure services and that utilise online delivery platforms. These types of business models are potentially less susceptible to disruptions caused by the pandemic compared with the broader economy. Nonetheless, the probability that we enter a global recession has increased considerably which brings with it significant challenges. OCI and Oakley Capital are taking a proactive approach to the situation and remain confident in the continued long-term performance of the Oakley Funds2. 

 

OCI balance sheet

 

· Net cash - the Company has no leverage and a strong balance sheet, with £152 million of net cash as at 25 March 2020. This represents 78p per share and 22% of NAV as at 31 December 2019. The Board continues to be comfortable with the cash position, which remains conservative, and is in continual dialogue with the Investment Adviser.

 

· Commitments - OCI has outstanding commitments to the Oakley Funds of £429 million at year end. £313 million of this is committed to the recently launched Fund IV, which will be deployed in new investments over a five-year period.

 

 

Portfolio companies & NAV impact

 

· Net Asset Value - while it is too early to fully evaluate, it is anticipated there will be an adverse effect on OCI's NAV as a result of COVID-19. The scale of the impact is dependent on many factors including the duration and severity of the virus, as well as the response from governments and consumers.

 

The recent significant fall in the OCI share price presented an attractive opportunity to continue the NAV per share-enhancing buy-back programme, with the purchase and cancellation of 3 million shares. This approach to capital management will continue, with further share buy-backs anticipated.

 

· Valuations - the fall in equity markets as a result of COVID-19 will put downward pressure on portfolio companies' valuations, where there are comparable publicly listed peers.

 

· Trading performance - over 70% of the portfolio companies operate a subscription-based or recurring revenue business model and are therefore less vulnerable to temporary declines in customer demand. In addition, 65% of the portfolio either deliver products or services digitally or have the ability to shift to digital delivery in a short time frame. While there will be an impact on trading, Oakley's sector focus has the potential to provide some resilience during this period of disruption.

 

Response from Oakley Capital

 

· Safety - the welfare of colleagues, investors, portfolio company employees and business partners is Oakley Capital's highest priority. Steps have been taken both to protect individuals and to provide support to our portfolio companies and management teams.

 

· Business continuity - the Oakley Capital team is well prepared with secure remote access and has continued to communicate and work without interruption.

 

· Response - risk assessments have been carried out on each of the portfolio companies and the team has confidence in the response plans that management teams are executing.

 

As a highly engaged investor, Oakley has strong lines of communications with all portfolio companies and is monitoring all businesses. This is especially important at times like these and as such the Oakley team is in constant dialogue with all portfolio companies to understand the impact and to support bespoke contingency planning, with a particular focus on liquidity and cash preservation in the short term. Oakley is also enabling the sharing of information, analysis and insights across all businesses.

 

· Investment - Fund III is currently 78% invested and as such has capital available to support and grow the current portfolio. With Fund IV currently 27% invested, it is also well positioned to partner with new investee companies as opportunities arise.

 

- ends -

 

For further information please contact:

 

Oakley Capital Limited

+44 20 7766 6900

Steven Tredget, Investor Relations

 

Greenbrook Communications Limited

+44 20 7952 2000

Alex Jones / Gina Bell / James Williams

 

Liberum Capital Limited (Financial Adviser & Broker)

+44 20 3100 2000

Gillian Martin / Owen Matthews

 

Notes:

LEI Number: 213800KW6MZUK12CQ815

About Oakley Capital Investments Limited ("OCI")

OCI is a Specialist Fund Segment ("SFS") traded investment vehicle, which provides access to the Oakley Funds2. It is a liquid vehicle that aims to provide capital growth and dividends to investors.

The Oakley Funds

Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III and Oakley Capital IV, are unlisted mid-market private equity funds with the aim of providing investors with significant long-term capital appreciation. The investment strategy of the funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement.

The Investment Adviser

Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.

Important information

Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules. The London Stock Exchange has not examined or approved the contents of the Prospectus.

The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDLZLLLBXLEBBF
Date   Source Headline
3rd Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20264:51 pmRNSResult of AGM
1st Jun 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSTransaction in Own Shares
26th May 20267:00 amRNSOakley Capital invests in XTEL
21st May 20267:00 amRNSTransaction in Own Shares
18th May 20267:00 amRNSTransaction in Own Shares
13th May 20267:00 amRNSTransaction in Own Shares
11th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSNotice of AGM
1st May 20267:00 amRNSTotal Voting Rights
30th Apr 20267:00 amRNSTransaction in Own Shares
29th Apr 20267:00 amRNSTrading update for the 3 months ended 31 March 26
24th Apr 20267:00 amRNSDirector Dealing
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSStandard form for notification of major holdings
17th Mar 20267:00 amRNSOakley Capital partners with Groupe Senef
17th Mar 20267:00 amRNSOakley Capital partners with Groupe Senef
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSFinal Results for the Year Ended 31 December 2025
12th Mar 20267:00 amRNSFinal Results for the Year Ended 31 December 2025
10th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSNotice of Results and Investor Presentation
3rd Mar 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSDirector Dealing
17th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 202612:05 pmRNS-RUpdate from QuotedData
11th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20263:26 pmRNSStandard form for notification of major holdings
6th Feb 20263:26 pmRNSStandard form for notification of major holdings
6th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20269:43 amRNS-RUpdate from QuotedData
4th Feb 20267:00 amRNSDirector Dealing
2nd Feb 20267:00 amRNSTotal Voting Rights
28th Jan 20267:00 amRNSTrading update for the year ended 31 December 2025
26th Jan 20267:00 amRNSStandard form for notification of major holdings
9th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20265:49 pmRNSStandard form for notification of major holdings
5th Jan 20267:00 amRNSOakley Capital invests in GLAS
5th Jan 20267:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
24th Dec 202511:18 amRNSStandard form for notification of major holdings
24th Dec 202511:18 amRNSStandard form for notification of major holdings
24th Dec 202511:04 amRNSTransaction in Own Shares
24th Dec 202511:04 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.